Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael J. Overman, Patricia LoRusso, John H. Strickler, Sandip Pravin Patel, Stephen John Clarke, Anne M. Noonan, Thiru Prasanna, Manik A. Amin, John J. Nemunaitis, Jayesh Desai, Kenneth John O'Byrne, Thomas J. George, Judson Englert, Dewei She, Zachary A. Cooper, Yuling Wu, Anis Khan, Rakesh Kumar, Johanna C. Bendell
Institutions: The University of Texas MD Anderson Cancer Center, Yale Cancer Center, Yale University, Duke University Health System, Duke Cancer Institute, University of California San Diego, Moores Cancer Center, Royal North Shore Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Chris O’Brien Lifehouse, Washington University in St. Louis, University of Toledo, The Royal Melbourne Hospital, Princess Alexandra Hospital, University of Florida, UF Health Cancer Center, Sarah Cannon
Language: English
Subfield: Physiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2892380094